Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000381461 | SCV000342256 | uncertain significance | not provided | 2016-07-07 | criteria provided, single submitter | clinical testing | |
Ce |
RCV000381461 | SCV000891982 | likely benign | not provided | 2022-09-01 | criteria provided, single submitter | clinical testing | TCIRG1: BP4, BP7 |
Labcorp Genetics |
RCV000381461 | SCV001106097 | likely benign | not provided | 2024-01-19 | criteria provided, single submitter | clinical testing | |
Illumina Laboratory Services, |
RCV001113576 | SCV001271360 | uncertain significance | Autosomal recessive osteopetrosis 1 | 2018-01-13 | criteria provided, single submitter | clinical testing | This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score, this variant could not be ruled out of causing disease and therefore its association with disease required further investigation. A literature search was performed for the gene, cDNA change, and amino acid change (if applicable). No publications were found based on this search. This variant was therefore classified as a variant of unknown significance for this disease. |
Natera, |
RCV001113576 | SCV001452921 | uncertain significance | Autosomal recessive osteopetrosis 1 | 2020-01-24 | no assertion criteria provided | clinical testing | |
Department of Pathology and Laboratory Medicine, |
RCV000381461 | SCV001552368 | uncertain significance | not provided | no assertion criteria provided | clinical testing | The TCIRG1 p.Gly599Gly variant was not identified in the literature nor was it identified in Cosmic or LOVD 3.0. The variant was identified in dbSNP (ID: rs150788130) and in ClinVar (classified as a VUS by EGL Genetics and Praxis fuer Humangenetik Tuebingen). The variant was also identified in control databases in 91 of 282564 chromosomes (1 homozygous) at a frequency of 0.000322 (Genome Aggregation Database Feb 27, 2017) and was observed in the following populations: Other in 9 of 7222 chromosomes (freq: 0.001246), European (Finnish) in 18 of 24946 chromosomes (freq: 0.000722), Latino in 21 of 35430 chromosomes (freq: 0.000593), European (non-Finnish) in 35 of 129092 chromosomes (freq: 0.000271), African in 6 of 24946 chromosomes (freq: 0.000241), Ashkenazi Jewish in 1 of 10364 chromosomes (freq: 0.000096) and East Asian in 1 of 19948 chromosomes (freq: 0.00005), while the variant was not observed in the South Asian population. The p.Gly599Gly variant is not expected to have clinical significance because it does not result in a change of amino acid and is not located in a known consensus splice site. However, 3 of 4 in silico or computational prediction software programs, (MaxEntScan, NNSPLICE, GeneSplicer) predict the creation of a new 5' splice site; this information is not predictive enough to assume pathogenicity. In summary, based on the above information the clinical significance of this variant cannot be determined with certainty at this time. This variant is classified as a variant of uncertain significance. |